Immunotherapy of murine leukemia following non-myeloablative conditioning with naïve or G-CSF mobilized blood or bone marrow stem cells

Cancer Immunology, Immunotherapy

Volumn 53, Issue 4, 2004, Pages 358-362

  Weiss, Lola ^a   Or, Reuven ^a   Slavin, Shimon ^a   Naparstek, Ella ^a   Reich, Shoshana ^a   Abdul Hai, Ali ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

G CSF; GVL; Murine leukemia; PBSC; SCT

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LEUKEMIA; CANCER IMMUNOTHERAPY; COLONY FORMING UNIT C; CONTROLLED STUDY; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MOUSE; MURINE LEUKEMIA; NONHUMAN; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL MOBILIZATION; T LYMPHOCYTE; TH1 CELL; WHOLE BODY RADIATION;

ANIMALS; BLOOD CELLS; BONE MARROW; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; LEUKEMIA, B-CELL; LEUKEMIA, EXPERIMENTAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 1642274937     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-003-0440-5     Document Type: Article

References (19)

1. Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T, Sanders J, Storb R, Buckner CD (1995) Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 85:1655
2. Bensinger WI, Clift R, Martin P, Appelbaum FR, Demirer T, Gooley T, Lilleby K, Rowley S, Sanders J, Storb R, Buckner CD (1996) Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation. Blood 88:2794
3. Dreger P, Haferlach T, Eckstein V, Jacobs S, Suttorp M, Loffler H, Muller-Ruchholtz W, Schmitz N (1994) G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol 87:609
4. Duhrsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D (1988) Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer. Blood 72:2074
5. Glass B, Uharek L, Hartung G, Zeis M, Steinmann J, Dreger P, Kronke M, Schmitz N (1998) Immunotherapeutic aspects of allogeneic peripheral progenitor cells. Bone Marrow Transplant 21 [Suppl 3]:S3
6. Korbling M, Przepiorka D, Huh YO, Engel H, van Besien K, Giralt S, Andersson B, Kleine HD, Seong D, Deisseroth AB, et al (1995) Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 85:1659
7. + Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 86:2842
8. Leshem B, Vourka Karussis U, Slavin S (2000) Correlation between enhancement of graft-vs-leukemia effects following allogeneic bone marrow transplantation by rIL-2 and increased frequency of cytotoxic T-lymphocyte precursors in murine myeloid leukemia. Cytokines Cell Mol Ther 6:141
9. Molineux G, Pojda Z, Dexter TM (1990) A comparison of hematopoiesis in normal and splenectomized mice treated with granulocyte colony-stimulating factor. Blood 75:563
10. Russell NH, Hunter A, Rogers S, Hanley J, Anderson D (1993) Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation (letter). Lancet 341:1482
11. Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Loffler H, Hunter A, Russell NH (1995) Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 85:1666
12. Schmitz N, Barrett J (2002) Optimizing engraftment - source and dose of stem cells. Semin Hematol (Review) 39:3
13. Slavin S, Strober S (1978) Spontaneous murine B-cell leukemia. Nature 272:624
14. Slavin S, Weiss L, Morecki S, Bassat HB, Leizerowitz R, Gamliel H, Korkesh A, Voss R, Polliack A. (1981) Ultrastructural, cell membrane and cytogenetic characteristics of B-cell leukemia (BCL1), a murine model of chronic lymphocytic leukemia. Cancer Res 41:4162
15. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R (1996) Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation. Blood 87:2195
16. Volpi I, Perruccio K, Tosti A, Capanni M, Ruggeri L, Posati S, Aversa F, Tabilio A, Romani L, Martelli MF, Velardi A (2001) Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood 97:2514
17. Weiss L, Reich S, Slavin S (1992) Use of recombinant human interleukein-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL2-activated cell-mediated immunotherapy. Cancer Invest 10:19
18. Weiss L, Lubin I, Factorowich I, Lapidot Z, Reich S, Reisner Y, Slavin S (1994) Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and rIL-2. J Immunol 153:2562
19. Weiss, Reich S, Slavin S (1999) The role of non-activated and rIL-2 activated CD4+ and CD8+ T cells in immunotherapy for leukemia. Cytokines Cell Mol Ther 5:153